Dymicron®, a privately held medical device company pioneering advanced spinal technologies, today announced the successful enrollment and treatment of the first patient in its Triadyme®-C Investigational Device Exemption (IDE) clinical trial. This milestone marks the initiation of a U.S. clinical study evaluating the safety and effectiveness of the Triadyme-C cervical artificial disc.